Based on discoveries made by Dr. Michel Cayouette and published in 2022, Numbio Therapeutics was founded in 2024 with the support of the IRCM’s Technology Transfer Office. This young biotechnology company, specializing in ophthalmology, is developing an innovative gene therapy targeting neurodegeneration caused by glaucoma. By focusing on modulating the Numb protein to reduce toxic levels of Tau in retinal ganglion cells, Numbio is paving the way for a unique approach capable of preserving vision and slowing the progression of the disease.
